H. Lundbeck A/S (HLUBF) Research

H. Lundbeck A/S is a biopharmaceutical firm dedicated to the discovery, development, manufacturing, and commercialization of pharmaceutical therapies primarily addressing psychiatric and neurological disorders, serving markets across Europe, North America, and other international regions. Its core product portfolio features medications such as Abilify Maintena for schizophrenia, Brintellix/Trintellix for depression, Northera for symptomatic neurogenic orthostatic hypotension, Vyepti for migraine prevention, and Rexulti/Rxulti, which treats both depression and schizophrenia. Beyond these flagship offerings, Lundbeck also provides specialized treatments like Azilect for Parkinson's disease, Cipralex/Lexapro for depression, Ebixa for Alzheimer's disease, Onfi for Lennox-Gastaut syndrome, Sabril for epilepsy, and Xenazine for chorea associated with Huntington's disease, among others. The company primarily distributes its pharmaceutical solutions through distributors, pharmacies, and hospitals. Lundbeck has strategic alliances, including a collaboration with Verantos focused on generating real-world evidence to support migraine therapy, and a partnership with Rgenta Therapeutics, Inc. Established in 1915, H. Lundbeck A/S maintains its corporate headquarters in Valby, Denmark.

Open H. Lundbeck A/S (HLUBF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.